GlassScriptPhysician profile
Alan Gadson Struth
NPI 1619990033
$6,033.26
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $565 · 2021: $1,205 · 2022: $1,628 · 2023: $1,153 · 2024: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,577.24 | 2019-2024 | Rinvoq |
| Amgen INC. | $916.59 | 2019-2024 | Enbrel, Otezla, Krystexxa |
| Pfizer INC. | $671.66 | 2019-2024 | |
| Janssen Biotech, INC. | $503.37 | 2021-2024 | Stelara, Remicade, Simponi Aria |
| Ucb, INC. | $479.04 | 2020-2023 | Cimzia |
| Lilly USA, LLC | $332.70 | 2019-2024 | Jardiance, Zepbound |
| Genzyme Corporation | $277.03 | 2019-2024 | |
| Novo Nordisk INC | $184.95 | 2020-2024 | Ozempic, Rybelsus |
| Celgene Corporation | $171.03 | 2019 | |
| Genentech USA, INC. | $134.55 | 2019-2021 | |
| Glaxosmithkline, LLC. | $121.58 | 2021-2024 | Benlysta |
| Allergan, INC. | $56.49 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $51.48 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.87 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $46.55 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $46.49 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $42.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $42.40 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $37.42 | 2021 | |
| Dexcom, INC. | $36.10 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $31.80 | 2022-2023 | Livalo, Seglentis |
| Mallinckrodt Hospital Products INC. | $30.64 | 2022 | |
| Fresenius Kabi USA, LLC | $20.20 | 2023 | Idacio |
| Hikma Pharmaceuticals USA | $19.59 | 2023 | Ryaltris, Mitigare, Kloxxado |
| Athena Bioscience, LLC | $19.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.86 | 2022 | |
| Antares Pharma, INC. | $16.99 | 2023 | Nocdurna, Tlando, Xyosted |
| Horizon Therapeutics Plc | $15.58 | 2023 | Krystexxa |
| Aytu Biopharma, INC. | $14.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.48 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.37 | 2022 | |
| Mallinckrodt Enterprises LLC | $13.84 | 2019 | |
| Eisai INC. | $13.72 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Struth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.